Pen(5)-Trp(7)-Orn(8)- urotensin II (4-11)

a urotensin II antagonist

Also Known As:

urotensin II (4-11), Pen(5)-Trp(7)-Orn(8)-; (Pen(5),DTrp(7),Orn(8))hU-II(4-11); 5-Pen-7-Trp-8-Orn-hU-II(4-11); urantide; urotensin II (4-11), penicillaminyl(5)-tryptophyl(7)-ornithyl(8)-

Networked: 28 relevant articles (3 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Hormones: 1347
    - Urotensins: 55
      - Pen(5)-Trp(7)-Orn(8)- urotensin II (4-11): 28
  - Peptide Fragments: 373
    - Pen(5)-Trp(7)-Orn(8)- urotensin II (4-11): 28
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Urotensins: 55
      - Pen(5)-Trp(7)-Orn(8)- urotensin II (4-11): 28
Biological Factors: 2472
- Inflammation Mediators: 1113
  - Autacoids: 276
    - Kinins: 2029
      - Urotensins: 55
        Pen(5)-Trp(7)-Orn(8)- urotensin II (4-11): 28

Experts

1.	Zhao, Juan: 6 articles (07/2021 - 06/2013)
2.	Grieco, Paolo: 5 articles (06/2014 - 07/2009)
3.	Novellino, Ettore: 4 articles (06/2014 - 07/2009)
4.	Li, Ying: 3 articles (07/2021 - 06/2014)
5.	Wang, Tu: 3 articles (07/2021 - 01/2020)
6.	Castel, Hélène: 3 articles (01/2021 - 10/2018)
7.	Desrues, Laurence: 3 articles (01/2021 - 10/2018)
8.	Xie, Ya-Qin: 3 articles (04/2020 - 06/2013)
9.	Xie, Lide: 2 articles (07/2021 - 01/2021)
10.	Cui, Haipeng: 2 articles (01/2021 - 01/2020)

Related Diseases

1.	Body Weight (Weight, Body) 12/20/2011 - "The pre-treatment control and pre-treatment model groups received urantide (0.6 mg/kg body weight) by a caudal vein injection. " 01/01/2021 - "Blood lipid levels, body weight, liver index and liver function were recovered in rats with AS after urantide treatment. " 01/01/2013 - "KK/upj-AY/J mice (KK) mice were divided into the following groups: KK group, with saline treatment for 2 weeks; KK+ urantide group, with daily 30 µg/kg body weight injections over the same time period of urantide, a potent urotensin II antagonist peptide; Non-diabetic C57BL/6J mice were used as normal controls. " 04/15/2020 - "Either body weight, renal functions of urea nitrogen, urine proteins and anion gaps or expression of kidney injury-related genes Agtr1α, Nox4, Cyba and Ncf1 were improved after AS rats were treated with urantide. "
2.	Fibrosis (Cirrhosis) 01/01/2023 - "It was found that the UT antagonist Urantide and exercise training improved DOX-induced cardiac insufficiency, reduced DOX-induced cardiomyocyte apoptosis, improved the structural disorder of myocardial fibers, and inhibited DOX-induced myocardial fibrosis. " 10/01/2017 - "Also in the model of TGF-β1-induced fibrosis, urantide and, to a greater extent, relaxin-2 were able to significantly lessen fibronectin expression (respectively, P<.05 and P<.01). " 10/01/2017 - "Our aim was to evaluate the role of urotensin II, urantide (urotensin II receptor antagonist) and relaxin-2 on the cellular expression of fibronectin as a surrogate marker for renal fibrosis. "
3.	Heart Failure 01/01/2019 - "Urantide treatment improved right heart failure parameters in MCT-induced PAH rats, thus providing a potential new strategy for treating PAH."
4.	Atherosclerosis 07/05/2021 - "This study aimed to investigate the effects of urantide on the JAK2/STAT3 signaling pathway in atherosclerosis. " 04/01/2020 - "In this study we investigated the role of macrophage-secreted UII in atherosclerosis progression, and evaluated the therapeutic value of urantide, a potent competitive UII receptor antagonist, in atherosclerosis treatment. " 07/05/2021 - "These results demonstrated that urantide may control the JAK2/STAT3 signaling pathway by antagonizing the UII/UT system, thereby maintaining the biological function of VSMCs and potentially preventing and curing atherosclerosis." 07/05/2021 - "We examined the effect of urantide on the UII/UT system and the JAK2/STAT3 signaling pathway in a high fat diet induced atherosclerosis rat model and studied the effect and mechanism of urantide on the phenotypic transformation of VSMCs. " 01/01/2021 - "Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway."
5.	Myocardial Ischemia (Ischemic Heart Diseases) 02/01/2008 - "This study is to investigate the protective effect of urantide against myocardial ischemia injury in mice and its mechanism. " 02/01/2008 - "Therefore urantide has significant protective effect against myocardial ischemia or A/R injury via the inhibition of Ca2+ overload and the augmentation of NO synthesis." 02/01/2008 - "[Protective effect of urantide against myocardial ischemia injury]." 05/01/2012 - "Therefore, our results demonstrate that urantide has a potent protective effect against myocardial ischemia-reperfusion injury in rats that may be involved with the PKC and PI3K-Akt signaling pathways." 05/01/2012 - "This study was designed to investigate whether the effect of urantide on myocardial ischemia-reperfusion injury in rats via the protein kinase C (PKC) and phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Urea (Carbamide)
3.	Nitrogen
4.	urotensin II
5.	Cytokines
6.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
7.	p38 Mitogen-Activated Protein Kinases
8.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
9.	Monocyte Chemoattractant Proteins
10.	Transforming Growth Factors (Transforming Growth Factor)

Related Therapies and Procedures

1.	Punctures
2.	Ligation
3.	Injections